Axsome Therapeutics (AXSM) Receivables - Net (2022 - 2025)
Historic Receivables - Net for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $215.8 million.
- Axsome Therapeutics' Receivables - Net rose 5596.52% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year increase of 5596.52%. This contributed to the annual value of $155.5 million for FY2024, which is 4489.84% up from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Receivables - Net is $215.8 million, which was up 5596.52% from $218.6 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' Receivables - Net ranged from a high of $218.6 million in Q2 2025 and a low of $16.2 million during Q2 2022
- In the last 4 years, Axsome Therapeutics' Receivables - Net had a median value of $111.2 million in 2023 and averaged $112.4 million.
- As far as peak fluctuations go, Axsome Therapeutics' Receivables - Net soared by 41375.17% in 2023, and later skyrocketed by 4489.84% in 2024.
- Quarter analysis of 4 years shows Axsome Therapeutics' Receivables - Net stood at $46.8 million in 2022, then soared by 129.34% to $107.3 million in 2023, then surged by 44.9% to $155.5 million in 2024, then soared by 38.8% to $215.8 million in 2025.
- Its Receivables - Net was $215.8 million in Q3 2025, compared to $218.6 million in Q2 2025 and $176.2 million in Q1 2025.